A MedTech company called Molbio Diagnostics has introduced Truenat MTB-INH to check for the presence of isoniazid resistance in Mycobacterium tuberculosis infections (MDR-TB). The test can yield results in an hour and has been validated and certified by CDSCO and ICMR.

Commenting on the launch, Dr. Sriram Natrajan, CEO, stated that the test will enable early and precise identification of the fatal illness at the initial patient encounter, which is essential to reaching eradication objectives. The detection of isonicotinic acid hydrazide (INH) resistance in Rifampicin-susceptible individuals is required by the revised WHO treatment recommendations for the treatment of Hr-TB patients. Therefore, identifying INH resistance is essential for the therapy and management of MDR-TB.

He added that once the test is introduced, all TB patients will have access to the test at the same TB testing center, which can now report the results on the same day. As a result, the treatment can be initiated, thereby enabling better treatment outcomes, and bringing down the spread of the disease. 

(Source: https://health.economictimes.indiatimes.com/news/diagnostics/molbio-launches-truenat-mtb-inh-test-for-drug-resistance-in-tb-patients/96963161 )